Lead Product(s) : Quemliclustat,Etrumadenant
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Taiho Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Taiho Exercises License Option for Quemliclustat in Japan and Asia
Details : Under the license agreement, Taiho will further support the development & commercialization of AB680 (quemliclustat) & will operationalize the PRISM-1 study in Japan as part of its mission.
Product Name : AB680
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 07, 2024
Lead Product(s) : Quemliclustat,Etrumadenant
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Taiho Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Quemliclustat,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Quemliclustat-Based Regimens Show Survival Promise in Metastatic Pancreatic Cancer
Details : AB680 (quemliclustat) is an investigational CD73 inhibitor undergoing phase 1 trials in combination with zimberelimab and chemotherapy for metastatic pancreatic cancer.
Product Name : AB680
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 16, 2024
Lead Product(s) : Quemliclustat,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Quemliclustat,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Gilead Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Quemliclustat-Based Regimens Show Promising Survival in Metastatic Pancreatic Cancer
Details : AB680 (quemliclustat) is an investigational small molecule CD73 inhibitor in phase 1 development, evaluated in combination with chemotherapy for treatment-naïve metastatic pancreatic cancer.
Product Name : AB680
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 16, 2024
Lead Product(s) : Quemliclustat,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Gilead Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Quemliclustat,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Preliminary data from the first dose-escalation cohorts, reported in an abstract released today, demonstrate encouraging signs of clinical activity for AB680 in combination with zimberelimab (anti-PD-1 antibody) and chemotherapy.
Product Name : AB680
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 01, 2021
Lead Product(s) : Quemliclustat,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable